ALGS
Aligos Therapeutics, Inc.
Key Financials
Operating Income
$-87985000
↑ 1.3%
Revenue
$2.2M
↓ 39.5%
Net Income
$-24193000
↑ 81.6%
Total Assets
$88.5M
↑ 26.3%
Cash & Equivalents
$18.3M
↓ 50.5%
Total Liabilities
$35.0M
↓ 64.7%
EPS (Diluted)
$-2.45
↑ 88.3%
Operating Cash Flow
$-82503000.00
↓ 2.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| 8-K | 6/26/2026 | View on SEC |
| SCHEDULE 13D | 6/24/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALGS |
| Company Name | Aligos Therapeutics, Inc. |
| CIK | 1799448 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (800) 466-6059 |